Role of suPAR in Periodontitis and CVD

University of Messina

Status

Completed

Conditions

Periodontal Diseases

Metabolic Disturbance

Treatments

Other: Observation of suPAR plasma and salivary levels

Study type

Observational

Funder types

Other

Identifiers

NCT04335344

11-18-18

Details and patient eligibility

About

soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.

Full description

The aim of this study was to evaluate a possible association between both saliva and serum suPAR levels in patients with CP and with CVD and if the serum suPAR levels are mediated by serum CRP.

Enrollment

326 patients

Sex

All

Ages

40 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Presence of at least 15 teeth
CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm;
Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion criteria

Intake of contraceptives
Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
Status of pregnancy or lactation
Previous history of excessive drinking
Allergy to local anaesthetic
Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.